EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Expansion of Splice-Switching Therapy with Antisense Oligonucleotides

Yasuhiro Takeshima iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26052270 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Yasuhiro Takeshima. Beteiligte Einrichtung: Department of Pediatrics, Hyogo Medical University, 1-1 Mukogawacho, Nishinomiya 663-8501, Japan. Hauptthemen laut MEDLINE: Oligonucleotides, Antisense, RNA Splicing, Genetic Therapy, Muscular Dystrophy, Duchenne. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education, Culture, Sports, Science, and Technology, Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Since 2016, splice-switching therapy, in which splicing is controlled by antisense oligonucleotides, has been applied in clinical practice for spinal muscular atrophy and Duchenne muscular dystrophy. In the former disease, this therapy induces exon inclusion, while, in the latter, it induces exon skipping, leading expression of functional proteins. Basic and clinical studies of splice-switching therapy for many monogenic diseases have now been conducted. The molecular mechanisms of splice-switching therapy include not only the induction of exon inclusion and skipping, but also the induction of pseudoexon skipping and suppression of splicing sites generated by mutations. In addition, therapies that alter protein function by regulating splicing are being investigated not only for monogenic diseases but also for non-monogenic ones such as cancer and immune-related disorders. It is expected that many of these basic studies will be translated into clinical applications. This review describes the current status of basic research and clinical applications of splice-switching therapy to promote the development of treatments for noncurable diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oligonucleotides, AntisenseRNA SplicingGenetic TherapyMuscular Dystrophy, DuchenneMuscular Atrophy, SpinalAlternative SplicingHumansAnimalsExons

Stichwörter der Autor:innen

antisense oligonucleotidemonogenic diseasenon-monogenic diseasesplice-switching therapy

Substanzen

Oligonucleotides, Antisense

Autor:innen und Institutionen

  • Department of Pediatrics, Hyogo Medical University, 1-1 Mukogawacho, Nishinomiya 663-8501, Japan.

ORCID-Profile: Yasuhiro Takeshima

Förderung

  • Ministry of Education, Culture, Sports, Science, and Technology, Japan

Zitieren

APA

Takeshima, Y. (2025). Expansion of Splice-Switching Therapy with Antisense Oligonucleotides. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26052270

Vancouver

Takeshima Y. Expansion of Splice-Switching Therapy with Antisense Oligonucleotides. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26052270

BibTeX
@article{Takeshima2025,
  author = {Takeshima, Yasuhiro},
  title = {Expansion of Splice-Switching Therapy with Antisense Oligonucleotides},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26052270}
}
Kostenlos starten →